Black Diamond Therapeutics Inc Ordinary Shares BDTX
News
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update